Indications
Ruxolitinib is a kinase inhibitor indicated for the treatment of:
- Intermediate or high-risk myelofibrosis in adults, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.
- Adult patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.
- Adult and pediatric patients 12 years of age and older with steroid-refractory acute graft-versus-host disease (GVHD).
- Adult and pediatric patients 12 years of age and older with chronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapy.
Dosage and Administration
Dosage should be individualized based on safety and efficacy. The starting doses for each indication are as follows:Myelofibrosis
The starting dose of Ruxolitinib is based on the patient’s baseline platelet count:
The starting dose of Ruxolitinib is based on the patient’s baseline platelet count:
- Greater than 200 × 10⁹/L: 20 mg twice daily
- 100 × 10⁹/L to 200 × 10⁹/L: 15 mg twice daily
- 50 × 10⁹/L to less than 100 × 10⁹/L: 5 mg twice daily
Monitor complete blood counts every 2 to 4 weeks until the dose is stable, then adjust as clinically indicated. Dose adjustments or interruptions may be required in the event of thrombocytopenia.
Polycythemia Vera
The starting dose of Ruxolitinib is 10 mg twice daily.
The starting dose of Ruxolitinib is 10 mg twice daily.
Acute Graft-Versus-Host Disease
The starting dose of Ruxolitinib is 5 mg twice daily.
The starting dose of Ruxolitinib is 5 mg twice daily.
Chronic Graft-Versus-Host Disease
The starting dose of Ruxolitinib is 10 mg twice daily.
The starting dose of Ruxolitinib is 10 mg twice daily.
Reviews
There are no reviews yet.